Therapeutic compounds for ovarian cancer
OwnerCharles A. Nicoletteinventor
Life of this patent
Estimating the term…
Abstract
The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response to presentation of these epitopes. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the compositions of the invention.
Claims9
A composition comprising at least two immunogenic ligands, wherein said immunogenic ligands are individually characterized by an ability to elicit an immune response against the same native ligand, and wherein said immunogenic ligand is selected from the group consisting of FLTDERMPV (SEQ ID NO:3), FLTDEARSV (SEQ ID NO:5), FLDDEIMRV (SEQ ID NO:7), FLDDEITFV (SEQ ID NO:9) and IIEDDRLPV (SEQ ID NO:11).
A host cell comprising at least two immunogenic ligands, wherein said immunogenic ligands are individually characterized by an ability to elicit an immune response against the same native ligand, and wherein said immunogenic ligand is selected from the group consisting of FLTDERMPV (SEQ ID NO:3), FLTDEARSV (SEQ ID NO:5), FLDDEIMRV (SEQ ID NO:7), FLDDEITFV (SEQ ID NO:9) and IIEDDRLPV (SEQ ID NO:11).
A method for inducing an immune response in a subject, comprising delivering to the subject a composition comprising an effective amount of two or more immunogenic ligands, wherein each of said immunogenic ligands is characterized by an ability to elicit an immune response against the same native ligand, and wherein said immunogenic ligand is selected from the group consisting of FLTDERMPV (SEQ ID NO:3), FLTDEARSV (SEQ ID NO:5), FLDDEIMRV (SEQ ID NO:7), FLDDEITFV (SEQ ID NO:9) and IIEDDRLPV (SEQ ID NO:11).
Dependencies are inferred from the claim text.